文献速递胃肠动力与功能性疾病

夜间平均基线阻抗与酸暴露时间不确定时反流症状疗效的相关性

Mean Nocturnal Baseline Impedance Correlates With Symptom Outcome When Acid Exposure Time Is Inconclusive on Esophageal Reflux Monitoring.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-06-01

回顾性队列研究纳入371例持续反流症状患者,在接受抑酸治疗外行pH-阻抗监测。MNBI低者在病理性及临界AET患者中与抗反流治疗症状改善相关,提示MNBI可补充AET评估食管反流负荷。

要点

  • MNBI低 (<2292欧姆) 在病理性AET患者中一致率为99.1%,临界AET为91.2%,生理性AET为33.7%。
  • 随访38.7±0.8个月,43.0%患者药物治疗症状改善,76.2%手术抗反流治疗症状改善 (P < .0001)。
  • MNBI低时,临界AET与病理性AET患者对药物治疗的反应无显著差异 (P = .44)。

核心结论

  • MNBI低时,可识别对针对病理性及临界AET且对抗反流治疗有反应的患者。
  • MNBI分析补充AET定义食管反流负荷,MNBI与症状对抗反流治疗的反应相关。

研究设计与样本

  • 回顾性队列研究,纳入371例治疗后持续反流症状患者,平均年龄54.5±0.7岁,女性占60.0%,在欧洲1个三级中心或美国1个三级中心行停用抑酸治疗后的动态pH-阻抗监测。

主要发现

  • 371例中107例 (28.8%) 为病理性AET,234例 (63.1%) 为MNBI异常。
  • MNBI低在病理性AET患者中一致率为99.1%,临界AET为91.2%,生理性AET为33.7%。
  • 随访38.7±0.8个月,43.0%患者药物治疗症状改善,76.2%手术抗反流治疗症状改善 (P < .0001)。
  • MNBI低时,临界AET与病理性AET患者对药物治疗的反应无显著差异 (P = .44);两组分别与生理性AET患者比较,无论MNBI正常或低,差异均有统计学意义 (每次比较P < .0001)。

关键数值与推荐

  • 总AET判定:病理性 >6%,生理性 <4%,临界或不确定 4%-6%。
  • MNBI在5-cm阻抗通道3个夜间10分钟时段计算并平均,异常定义为 <2292欧姆。
  • 主要结局为抗反流治疗反应,定义为标准化视觉模拟量表上整体症状改善≥50%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Abnormal acid exposure time (AET) is associated with good outcomes of symptoms from antireflux therapy. Low esophageal mean nocturnal baseline impedance (MNBI) is an additional marker of reflux disease. We aimed to evaluate the value of MNBI when analysis of AET produces borderline or inconclusive results. METHODS: We studied a retrospective cohort of 371 patients (mean age, 54.5 ± 0.7 y; 60.0% female) who had persistent reflux symptoms after treatment and underwent ambulatory pH-impedance monitoring off antisecretory therapy at 1 tertiary center in Europe or 1 in the United States. Total AET was determined from pH impedance studies (pathologic, >6%; physiologic, <4%; borderline or inconclusive, 4%-6%). Baseline impedance values were calculated at the 5-cm impedance channel at 3 nocturnal 10-minute periods and averaged to yield MNBI (abnormal, <2292 ohms). The primary outcome was response to antireflux therapy, defined as global symptom improvement of 50% or greater on patients' answers on standardized visual analog scales. RESULTS: Among the 371 patients, 107 (28.8%) had pathologic AET and 234 (63.1%) had abnormal MNBI. Low MNBI was concordant in 99.1% of patients with pathologic AET, in 91.2% with borderline AET, and in 33.7% with physiologic AET. During 38.7 ± 0.8 months of follow-up evaluation, 43.0% of patients had improved symptoms with medical therapy and 76.2% had improved symptoms with surgical antireflux therapy (P < .0001). When MNBI was low, response to medical therapy did not differ significantly between patients with borderline AET and patients with pathologic AET (P = .44), but did differ significantly when each group was compared with patients with physiologic AET, regardless of whether MNBI was normal or low (P < .0001 for each comparison). CONCLUSIONS: When low, MNBI identifies patients with pathologic and borderline AET who respond to antireflux therapy. MNBI analysis complements AET in defining esophageal reflux burden. MNBI correlates with response of symptoms to antireflux therapy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rengarajan A, Savarino E, Della Coletta M, et al. Mean Nocturnal Baseline Impedance Correlates With Symptom Outcome When Acid Exposure Time Is Inconclusive on Esophageal Reflux Monitoring. Clin Gastroenterol Hepatol. 2019. PMID: 31163276. doi:10.1016/j.cgh.2019.05.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。